Vtesse Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $200M

Vtesse General Information

Description

Developer of new drug treatments designed to treat severe and life-threatening diseases. The company's new drug treatments, includes treatment for rare disease Niemann-Pick Disease Type C (NPC), enabling patients with NPC and other lysosomal storage diseases to get treated. It also offers information, resources and support that can be used to better understand NPC and to cope with its impact on lives.

Contact Information

Website
www.vtessepharma.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 910 Clopper Road
  • Suite 220 South
  • Gaithersburg, MD 20878
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Information Services (B2C)
Acquirer
Sucampo Pharmaceuticals
Vertical(s)
TMT
Corporate Office
  • 910 Clopper Road
  • Suite 220 South
  • Gaithersburg, MD 20878
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vtesse Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 03-Apr-2017 $200M Completed Startup
2. Early Stage VC (Series A) 25-Jul-2016 Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Clinical Trials - Phase 2
To view Vtesse’s complete valuation and funding history, request access »

Vtesse Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Vtesse’s complete cap table history, request access »

Vtesse Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of new drug treatments designed to treat severe and life-threatening diseases. The company's new drug treatmen
Drug Discovery
Gaithersburg, MD
10 As of 2017

Clarksville, MD
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vtesse Competitors (18)

One of Vtesse’s 18 competitors is NeuroNascent, a Venture Capital-Backed company based in Clarksville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NeuroNascent Venture Capital-Backed Clarksville, MD
Neurona Therapeutics Venture Capital-Backed South San Francisco, CA
CuraSen Venture Capital-Backed San Carlos, CA
Ralexar Therapeutics Venture Capital-Backed Wayne, PA
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
You’re viewing 5 of 18 competitors. Get the full list »

Vtesse Patents

  • 6

    Total Documents Applications and Grants

  • Total Patents Families

  • 1

    Granted

  • Pending

  • Expiring in next 12 mo

Vtesse Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160361345-A1 Hydroxypropyl beta-cyclodextrin compositions and methods Inactive 10-Jun-2015
EP-3307278-A4 Hydroxypropyl beta-cyclodextrin compositions and methods Inactive 10-Jun-2015
AU-2016276774-A1 Hydroxypropyl beta-cyclodextrin compositions and methods Inactive 10-Jun-2015
EP-3307278-A1 Hydroxypropyl beta-cyclodextrin compositions and methods Inactive 10-Jun-2015
CA-2988529-A1 Hydroxypropyl beta-cyclodextrin compositions and methods Inactive 10-Jun-2015 A61K31/724
To view Vtesse’s complete patent history, request access »

Vtesse Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vtesse Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Venture Investments Venture Capital Minority
Bay City Capital Venture Capital Minority
Cydan Accelerator/Incubator Minority
Lundbeckfonden BioCapital Venture Capital Minority
New Enterprise Associates Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Vtesse FAQs

  • When was Vtesse founded?

    Vtesse was founded in 2014.

  • Where is Vtesse headquartered?

    Vtesse is headquartered in Gaithersburg, MD.

  • What is the size of Vtesse?

    Vtesse has 10 total employees.

  • What industry is Vtesse in?

    Vtesse’s primary industry is Drug Discovery.

  • Is Vtesse a private or public company?

    Vtesse is a Private company.

  • What is the current valuation of Vtesse?

    The current valuation of Vtesse is .

  • What is Vtesse’s current revenue?

    The current revenue for Vtesse is .

  • How much funding has Vtesse raised over time?

    Vtesse has raised $42M.

  • Who are Vtesse’s investors?

    Alexandria Venture Investments, Bay City Capital, Cydan, Lundbeckfonden BioCapital, and New Enterprise Associates are 5 of 6 investors who have invested in Vtesse.

  • Who are Vtesse’s competitors?

    NeuroNascent, Neurona Therapeutics, CuraSen, Ralexar Therapeutics, and Aro Biotherapeutics are some of the 18 competitors of Vtesse.

  • When was Vtesse acquired?

    Vtesse was acquired on 03-Apr-2017.

  • Who acquired Vtesse?

    Vtesse was acquired by Sucampo Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »